.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
McKinsey
Express Scripts
Mallinckrodt
US Department of Justice
Baxter
Boehringer Ingelheim
UBS
Moodys
Merck

Generated: November 25, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,345,714

« Back to Dashboard

Which drugs does patent 9,345,714 protect, and when does it expire?


Patent 9,345,714 protects CIPRODEX and is included in one NDA. There has been one Paragraph IV challenge on Ciprodex.

This patent has eighteen patent family members in sixteen countries.

Summary for Patent: 9,345,714

Title:Method of treating middle ear infections
Abstract: Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.
Inventor(s): Wall; G. Michael (Fort Worth, TX), Conroy; Peter J. (Fort Worth, TX)
Assignee: Alcon Pharmaceuticals Ltd. (Fribourg, CH)
Application Number:14/838,637
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms Corp
CIPRODEX
ciprofloxacin; dexamethasone
SUSPENSION/DROPS;OTIC021537-001Jul 18, 2003RXYesYes► Subscribe► SubscribeY TREATMENT OF ACUTE OTITIS MEDIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,345,714

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,846,650Method of treating middle ear infections► Subscribe
9,402,805Method of treating middle ear infections► Subscribe
9,149,486Method of treating middle ear infections► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,345,714

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria313328► Subscribe
Australia2002333671► Subscribe
Brazil0212898► Subscribe
Canada2459930► Subscribe
China1231218► Subscribe
China1555267► Subscribe
Germany60208216► Subscribe
Denmark1429780► Subscribe
European Patent Office1429780► SubscribeCA 2012 00045Denmark► Subscribe
European Patent Office1429780► Subscribe13C0012France► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
US Department of Justice
Citi
Mallinckrodt
Cantor Fitzgerald
Cerilliant
US Army
Express Scripts
Chinese Patent Office
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot